The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial reduction in body mass and enhance metabolic marke